What is Burkitt Lymphoma in Pediatrics
Burkitt lymphoma is the most common aggressive mature B-cell non-Hodgkin lymphoma in children, characterized by extremely rapid proliferation and MYC gene dysregulation, but is highly curable with modern intensive chemotherapy, achieving 5-year survival rates of 91% in children aged 14 and younger. 1
Disease Classification and Epidemiology
Burkitt lymphoma accounts for 5-7% of all pediatric cancers depending on age group, representing the predominant subtype of pediatric NHL 1. The disease exists in three distinct epidemiologic variants 1:
- Sporadic form: Occurs in North America and Europe, approximately 15% EBV-positive, commonly presents with abdominal involvement (abdomen, lymph nodes, bone marrow, or CSF)
- Endemic form: Associated with EBV in ~95% of cases, occurs in equatorial Africa where it accounts for up to 70% of childhood cancers, typically presents in jaw, orbit, mesentery, and CNS, strongly linked to malaria exposure
- Immunodeficiency-associated: Primarily in HIV patients (may be AIDS-defining), up to 70% EBV-positive
Clinical Presentation Patterns
The clinical presentation varies dramatically by anatomic site and can mimic common benign pediatric conditions, creating diagnostic pitfalls:
Abdominal presentations (most common in sporadic form):
- Chronic abdominal pain, diarrhea, weight loss mimicking appendicitis or inflammatory bowel disease 2
- Ileocecal involvement causing intussusception 3
- Isolated gastrointestinal bleeding from rectal or gastric masses 4, 5
- Rapidly enlarging cecal or ileal masses 2, 3
Head and neck presentations:
- Rapidly progressive mandibular swelling initially mistaken for dental abscess or odontogenic infection 6
- Jaw involvement particularly in endemic variant 1
Key diagnostic red flags: Persistent symptoms despite initial treatment, markedly elevated lactate dehydrogenase, leukocytosis, and elevated ESR should raise immediate suspicion 2.
Pathologic and Molecular Features
The diagnosis requires recognition of characteristic histopathologic features 6, 7:
- Monomorphic medium-sized atypical lymphoid cells with high mitotic activity
- Classic "starry-sky" appearance (scattered tingible body macrophages among densely packed lymphoid cells) 3
- Immunophenotype: CD20+, CD10+, BCL6+, c-MYC+
- Ki-67 proliferation index approaching 95-100% (reflecting extreme proliferative rate) 6
- MYC gene translocation, most commonly t(8;14) 3, 7
Critical caveat: Initial biopsies can be falsely negative, showing only minimal histiocytosis without evidence of malignancy 2. When clinical suspicion remains high despite negative initial biopsy, repeat tissue sampling is mandatory.
Imaging Characteristics
Radiologic features vary by location but share common aggressive patterns 8:
- Ill-defined osteolytic lesions with cortical erosion in bone involvement 6
- Large, heterogeneous masses with soft tissue extension
- Associated lymphadenopathy
- Rapid growth between imaging studies
Prognosis and Treatment Urgency
Burkitt lymphoma is highly aggressive but highly curable 1. The 5-year survival rate reaches 91% in children aged 14 and younger and 88% in adolescents 15-19 years 1. With modern risk-adapted chemo-immunotherapy regimens including rituximab, overall survival rates reach 80-90% in young patients 7.
Treatment must occur at specialized centers with expertise in pediatric aggressive B-cell lymphomas 1. The complexity of intensive multi-agent chemotherapy and potential for severe complications (tumor lysis syndrome, CNS involvement) necessitates experienced multidisciplinary teams.
Poor prognosis is primarily associated with refractory or relapsed disease 7. Early diagnosis and prompt initiation of therapy are critical given the tumor's doubling time measured in hours to days.
Key Clinical Takeaways
- Maintain extremely high suspicion in children with persistent GI symptoms, unexplained mandibular swelling, or rapidly enlarging masses
- Do not be falsely reassured by negative initial biopsy—repeat sampling if clinical suspicion persists
- Markedly elevated LDH is a critical laboratory clue
- Immediate referral to pediatric oncology is mandatory once diagnosis is suspected
- The disease is curable despite its aggressive nature, but delays in diagnosis significantly worsen outcomes